{"title": "La vacuna Nuvaxovid\u2122 de Novavax contra la COVID-19 se autoriza de forma condicional en la Uni\u00f3n Europea para adolescentes de 12 a 17 a\u00f1os", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/la-vacuna-nuvaxovid-tm-de-novavax-contra-la-covid-19-se-autoriza-de-forma-condicional-en-la-union-europea-para-adolescentes-de-12-a-17-anos-862528667.html", "hostname": "prnewswire.com", "description": "/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnolog\u00eda dedicada a desarrollar y comercializar vacunas de \u00faltima generaci\u00f3n para...", "sitename": "PR Newswire", "date": "2022-07-06", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "La vacuna Nuvaxovid\u2122 de Novavax contra la COVID-19 se autoriza de forma condicional en la Uni\u00f3n Europea para adolescentes de 12 a 17 a\u00f1os\n[Novavax, Inc.](/news/novavax%2C-inc./)\n06 Jul, 2022, 10:16 ET\n[]\n- La vacuna Nuvaxovid\u2122 contra la COVID-19 es la primera opci\u00f3n basada en prote\u00ednas para adolescentes de 12 a 17 a\u00f1os en Europa\nGAITHERSBURG, Md., 6 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una empresa de biotecnolog\u00eda dedicada a desarrollar y comercializar vacunas de \u00faltima generaci\u00f3n para enfermedades infecciosas graves, anunci\u00f3 hoy que la Comisi\u00f3n Europea (CE) autoriz\u00f3 la ampliaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n condicional (CMA) de la vacuna Nuvaxovid\u2122 (NVX-CoV2373) contra la COVID-19 en la Uni\u00f3n Europea (UE) para adolescentes de 12 a 17 a\u00f1os. La aprobaci\u00f3n sigue a la recomendaci\u00f3n positiva formulada por el Comit\u00e9 de medicamentos de uso humano de la Agencia Europea de Medicamentos el [23 de junio de 2022.](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2861931460&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4051581382%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-23-Novavax-COVID-19-Vaccine-Nuvaxovid-TM-Recommended-for-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-by-CHMP-for-Adolescents-Aged-12-Through-17%26a%3DJune%2B23%252C%2B2022&a=23+de+junio+de+2022.)\n\"Con esta autorizaci\u00f3n, nos complace enormemente poder ofrecer nuestra vacuna Nuvaxovid contra la COVID-19 a los adolescentes de la Uni\u00f3n Europea\", afirm\u00f3 Stanley C. Erck, presidente y director ejecutivo de Novavax. \"Nuestra vacuna basada en prote\u00ednas se desarroll\u00f3 utilizando un enfoque innovador de la tecnolog\u00eda tradicional y ha demostrado eficacia y seguridad tanto en adolescentes como en adultos\".\nLa autorizaci\u00f3n se bas\u00f3 en datos de la\n[expansi\u00f3n pedi\u00e1trica](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=972467163&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3028641640%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3Dpediatric%2Bexpansion&a=expansi%C3%B3n+pedi%C3%A1trica) en curso de PREVENT-19, un ensayo pivotal de fase 3 con 2.247 adolescentes de 12 a 17 a\u00f1os en 73 centros de los Estados Unidos para evaluar la seguridad, efectividad (inmunogenicidad) y eficacia de Nuvaxovid. En el ensayo, Nuvaxovid logr\u00f3 su criterio de valoraci\u00f3n primario de efectividad en el ensayo y demostr\u00f3 una eficacia cl\u00ednica del 80 % en general en un momento en que la variante delta era la cepa circulante de SARS-CoV-2 predominante en los Estados Unidos.\nLos datos preliminares de seguridad del ensayo mostraron que la vacuna es en general bien tolerada. Los efectos adversos graves y severos fueron escasos en n\u00famero y equilibrados entre el grupo al que se le administr\u00f3 la vacuna y el que recibi\u00f3 el placebo, y no se consideraron relacionados con la vacuna. La reactogenicidad local y sist\u00e9mica fue generalmente menor o similar a la de los adultos despu\u00e9s de la primera y la segunda dosis. Las reacciones adversas m\u00e1s comunes observadas fueron sensibilidad/dolor en el sitio de la inyecci\u00f3n, dolor de cabeza, mialgia, fatiga y malestar. No hubo aumento de la reactogenicidad en los adolescentes m\u00e1s j\u00f3venes (de 12 a <15 a\u00f1os) en comparaci\u00f3n con los mayores (de 15 a <18 a\u00f1os). No se observ\u00f3 ninguna nueva se\u00f1al de seguridad en la porci\u00f3n del estudio que fue controlada con placebo.\nLa Comisi\u00f3n Europea otorg\u00f3 la autorizaci\u00f3n de comercializaci\u00f3n condicional (CMA) a Nuvaxovid para la prevenci\u00f3n de la COVID-19 en personas de 18 a\u00f1os o m\u00e1s en\n[diciembre de 2021](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2632041598&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D697197056%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D3782079808%2526u%253Dhttps%25253A%25252F%25252Fir.novavax.com%25252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%2526a%253DDecember%26a%3DDecember%2B2021&a=diciembre+de+2021). Adem\u00e1s de la autorizaci\u00f3n de comercializaci\u00f3n condicional (CMA) ampliada, [India](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=574237381&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3307428078%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-03-22-Novavax-and-Serum-Institute-of-India-Announce-First-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-Adolescents-12-to-18-in-India%26a%3DIndia&a=India) ha otorgado autorizaci\u00f3n para el uso de emergencia en la poblaci\u00f3n de 12 a 17 a\u00f1os.\nAutorizaci\u00f3n en los Estados Unidos\nLa NVX-CoV2373 a\u00fan no ha sido autorizada para su uso en los Estados Unidos y el nombre comercial Nuvaxovid\u2122 a\u00fan no ha sido aprobado por la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos.\nInformaci\u00f3n importante de seguridad\n- Nuvaxovid est\u00e1 contraindicada para personas que tienen hipersensibilidad a la sustancia activa o a cualquiera de los excipientes de esta vacuna.\n- Se han reportado eventos de anafilaxia con la administraci\u00f3n de vacunas contra la COVID-19. Se debe disponer de tratamiento m\u00e9dico y supervisi\u00f3n adecuados en caso de una reacci\u00f3n anafil\u00e1ctica tras la administraci\u00f3n de la vacuna. Se recomienda observaci\u00f3n cercana durante al menos 15 minutos y no se debe administrar una segunda dosis de la vacuna a quienes hayan experimentado anafilaxia con la primera dosis de Nuvaxovid.\n- Pueden ocurrir reacciones asociadas con la ansiedad en conexi\u00f3n con la vacuna, entre ellas reacciones vasovagales (s\u00edncope), hiperventilaci\u00f3n o reacciones relacionadas al estr\u00e9s, como respuesta psicog\u00e9nica a la inyecci\u00f3n con aguja. Es importante que se tomen precauciones para evitar lesiones por desmayo.\n- Se debe posponer la vacunaci\u00f3n en personas que padezcan una enfermedad febril grave aguda o una infecci\u00f3n aguda. La presencia de una infecci\u00f3n menor y/o fiebre baja no deber\u00edan retrasar la vacunaci\u00f3n.\n- Nuvaxovid se deber\u00eda administrar con precauci\u00f3n a las personas que est\u00e9n recibiendo terapia anticoagulante, o a aquellas que padezcan trombocitopenia o cualquier trastorno de la coagulaci\u00f3n (como la hemofilia), ya que pueden producirse hemorragias o hematomas despu\u00e9s de la administraci\u00f3n intramuscular de la vacuna en estas personas.\n- La eficacia de Nuvaxovid puede ser menor en las personas inmunodeprimidas.\n- La administraci\u00f3n de Nuvaxovid durante el embarazo solo debe considerarse cuando los beneficios potenciales superan cualquier riesgo potencial para la madre y el feto.\n- Los efectos de Nuvaxovid pueden afectar temporalmente la capacidad de conducir u operar m\u00e1quinas.\n- Es posible que las personas no est\u00e9n plenamente protegidas hasta siete d\u00edas despu\u00e9s de haber recibido su segunda dosis. Al igual que con todas las vacunas, es posible que la inmunizaci\u00f3n con Nuvaxovid no proteja a todos los receptores de la vacuna.\n- Las reacciones adversas m\u00e1s comunes que se observaron durante los estudios cl\u00ednicos fueron dolor de cabeza, n\u00e1useas o v\u00f3mitos, mialgia, artralgia, sensibilidad/dolor en el sitio de la inyecci\u00f3n, fatiga y malestar.\nPara obtener m\u00e1s informaci\u00f3n sobre Nuvaxovid, visite los siguientes sitios web:\nAcerca de NVX-CoV2373\nNVX-CoV2373 es una vacuna basada en prote\u00ednas dise\u00f1ada a partir de la primera cepa del SARS-CoV-2, el virus que causa la enfermedad COVID-19. La vacuna fue creada utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar ant\u00edgenos derivados de la prote\u00edna de espiga (S) del coronavirus y est\u00e1 formulada con Matrix-M\u2122, el adyuvante basado en saponinas patentado de Novavax, para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes. NVX-CoV2373 contiene ant\u00edgenos de prote\u00edna purificados y no puede replicarse ni causar COVID-19.\nLa vacuna Novavax contra la COVID-19 se empaca como una formulaci\u00f3n l\u00edquida lista para su uso en un vial que contiene diez dosis. El r\u00e9gimen de vacunaci\u00f3n consiste en dos dosis de 0,5 ml (5 mcg de ant\u00edgeno y 50 mcg del adyuvante Matrix-M\u2122) administradas por v\u00eda intramuscular con un intervalo de 21 d\u00edas. La vacuna se almacena en un rango de temperatura entre 2 y 8 \u00b0C, lo que permite el uso de los canales de suministro de vacunas y de la cadena de fr\u00edo existentes. El uso de la vacuna est\u00e1 sujeto a las recomendaciones oficiales.\nNovavax ha formado alianzas para la fabricaci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n de la NVX-CoV2373 en todo el mundo. Las autorizaciones existentes aprovechan la alianza de fabricaci\u00f3n de Novavax con Serum Institute of India, el fabricante de vacunas m\u00e1s grande del mundo en cuanto a volumen. M\u00e1s adelante, se complementar\u00e1 con datos de otras plantas de fabricaci\u00f3n en la cadena de suministro global de Novavax.\nAcerca de los ensayos de fase 3 de la NVX-CoV2373\nLa NVX-CoV2373 contin\u00faa en evaluaci\u00f3n mediante dos ensayos pivotales de fase 3.\nPREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19 (\"Ensayo de eficacia de la vacuna de subunidad de prote\u00edna de prefusi\u00f3n) es un estudio 2:1 aleatorizado, controlado por placebo y ciego para el observador que busca evaluar la eficacia, la seguridad y la inmunogenicidad de NVX-CoV2373 con el adyuvante Matrix-M en 29.960 participantes de 18 a\u00f1os de edad y mayores en 119 puntos de los Estados Unidos y M\u00e9xico. El criterio de valoraci\u00f3n primario de PREVENT-19 fue la primera aparici\u00f3n de COVID-19 sintom\u00e1tica confirmada por PCR (leve, moderada o grave) con inicio al menos siete d\u00edas despu\u00e9s de la aplicaci\u00f3n de la segunda dosis en participantes adultos seronegativos (al SARS-CoV-2) al inicio del estudio. El criterio de \u00e9xito estad\u00edstico incluy\u00f3 un l\u00edmite inferior de 95 % IC >30 %. Un criterio de valoraci\u00f3n secundario fue la prevenci\u00f3n de la COVID-19 sintom\u00e1tica moderada o grave confirmada por PCR. Ambos criterios de valoraci\u00f3n fueron evaluados al menos siete d\u00edas despu\u00e9s de la segunda vacuna del estudio en voluntarios que no se hab\u00edan infectado previamente con el SARS-CoV-2. En el ensayo, la NVX-CoV2373 logr\u00f3 una eficacia general del 90,4 %. En general, fue bien tolerada y provoc\u00f3 una s\u00f3lida respuesta de anticuerpos tras la segunda dosis en ambos estudios. Los resultados completos del ensayo se publicaron en el\n[New England Journal of Medicine](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=599448890&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1671020019%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine) (NEJM).\nLa expansi\u00f3n pedi\u00e1trica de PREVENT-19 es un ensayo 2:1 aleatorizado, controlado por placebo y ciego para el observador que busca evaluar la seguridad, efectividad y eficacia de NVX-CoV2373 con el adyuvante Matrix-M en 2.247 participantes adolescentes de 12 a 17 a\u00f1os en 73 ubicaciones de los Estados Unidos en comparaci\u00f3n con el uso de placebo. En el ensayo pedi\u00e1trico, la NVX-CoV2373 alcanz\u00f3 su criterio de valoraci\u00f3n primario de efectividad (no inferioridad de la respuesta de anticuerpos neutralizantes en comparaci\u00f3n con los participantes adultos j\u00f3venes de 18 a 25 a\u00f1os de edad de PREVENT-19) y demostr\u00f3 una eficacia global del 80 % en un momento en el que la variante delta de inter\u00e9s era la cepa circulante predominante en los EE. UU. Adem\u00e1s, las respuestas inmunitarias fueron de dos a tres veces mayores en los adolescentes que en los adultos contra todas las variantes estudiadas.\nEl estudio PREVENT-19 se lleva a cabo con apoyo del gobierno de los Estados Unidos, incluido el Departamento de Defensa, la Autoridad de Investigaci\u00f3n y Desarrollo Avanzado Biom\u00e9dico (BARDA), parte de la Subsecretar\u00eda de Preparaci\u00f3n y Respuesta del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) y el Instituto Nacional de Alergias y Enfermedades Infecciosas, parte de los Institutos Nacionales de Salud del HHS. BARDA aporta hasta USD 1.750 millones en virtud de un acuerdo con el Departamento de Defensa (#MCDC2011-001).\nAdem\u00e1s, en un ensayo realizado en el Reino Unido con 14.039 participantes de 18 a\u00f1os o m\u00e1s, aleatorizado, controlado con placebo y ciego para el observador, se logr\u00f3 una eficacia general del 89,7 %. El criterio de valoraci\u00f3n primario se bas\u00f3 en la primera aparici\u00f3n de COVID-19 sintom\u00e1tica (leve, moderada o grave) confirmada por PCR, con inicio al menos siete d\u00edas despu\u00e9s de la aplicaci\u00f3n de la segunda vacuna del estudio en participantes adultos serol\u00f3gicamente negativos (al SARS-CoV-2) al inicio del estudio. Los resultados completos del ensayo se publicaron en el\n[NEJM](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4040707067&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2148733100%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM).\nAcerca del adyuvante Matrix-M\u2122\nEl adyuvante Matrix-M\u2122 basado en saponinas patentado de Novavax ha demostrado un efecto potente y bien tolerado al estimular la entrada de c\u00e9lulas que presentan ant\u00edgenos en el sitio de la inyecci\u00f3n y mejorar la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales, lo que potencia la respuesta inmune.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)) es una compa\u00f1\u00eda de biotecnolog\u00eda que promueve la mejora de la salud a nivel mundial mediante el descubrimiento, el desarrollo y la comercializaci\u00f3n de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnolog\u00eda recombinante patentada de la compa\u00f1\u00eda aprovecha el poder y la velocidad de la ingenier\u00eda gen\u00e9tica para producir de manera eficiente nanopart\u00edculas altamente inmunog\u00e9nicas dise\u00f1adas para atender las necesidades urgentes de salud en todo el mundo. NVX-CoV2373, la vacuna contra la COVID-19 de la empresa, ha recibido autorizaci\u00f3n condicional de m\u00faltiples autoridades regulatorias a nivel mundial, incluida la Comisi\u00f3n Europea y la Organizaci\u00f3n Mundial de la Salud. La vacuna est\u00e1 siendo revisada por m\u00faltiples agencias reguladoras en todo el mundo y pronto lo ser\u00e1 en los EE. UU. para su uso en adultos, adolescentes y como refuerzo. Adem\u00e1s de su vacuna contra la COVID-19, Novavax tambi\u00e9n est\u00e1 evaluando actualmente un candidato a vacuna combinada contra la gripe estacional y la COVID en un ensayo cl\u00ednico de fase 1/2, que combina la NVX-CoV2373 y NanoFlu*, su candidato a vacuna tetravalente contra la gripe en fase de investigaci\u00f3n, y tambi\u00e9n est\u00e1 evaluando una vacuna basada en la cepa \u00f3micron (NVX-CoV2515), as\u00ed como una vacuna bivalente basada en las cepas \u00f3micron y original. Ambas candidatas a vacuna incorporan el adyuvante Matrix-M basado en saponina patentado de Novavax para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes.\nPara obtener m\u00e1s informaci\u00f3n, visite\n[www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=132730778&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1672205823%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com) y con\u00e9ctese con nosotros en\n*NanoFlu identifica una candidata a vacuna contra la influenza por nanopart\u00edculas de prote\u00ednas recombinantes de hemaglutinina (HA) producida por Novavax. Esta candidata en investigaci\u00f3n fue evaluada durante un ensayo controlado de fase 3 realizado durante la temporada de influenza 2019-2020.\nDeclaraciones prospectivas\nLas declaraciones aqu\u00ed contenidas relacionadas con el futuro de Novavax, sus planes y perspectivas operacionales, sus alianzas, el cronograma de resultados de ensayos cl\u00ednicos, el desarrollo en curso de la NVX-CoV2373, una candidata a vacuna estacional contra la COVID en investigaci\u00f3n, el alcance, los plazos y los resultados de futuras postulaciones y acciones normativas, incluidos los planes de Novavax de complementar autorizaciones existentes con informaci\u00f3n de las plantas adicionales de fabricaci\u00f3n en la cadena global de suministro de Novavax, autorizaciones mundiales adicionales de NVX-CoV2373 para adolescentes, el impacto potencial y alcance de Novavax y la NVX-CoV2373 para atender el acceso a la vacuna, controlar la pandemia y proteger las poblaciones, as\u00ed como la eficacia, la seguridad y el uso esperado de la NVX-CoV2373, constituyen declaraciones prospectivas. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran sustancialmente de los expresados o impl\u00edcitos por dichas declaraciones. Estos riesgos e incertidumbres incluyen, entre otros, desaf\u00edos que satisfacen, por s\u00ed solos o junto con sus socios, varios requerimientos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los que se relacionan con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras correspondientes; la dificultad para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, sobre la capacidad de Novavax para seguir v\u00edas regulatorias planificadas; dificultades para cumplir los requerimientos contractuales en virtud de acuerdos con diversas entidades comerciales, gubernamentales y de otros tipos; y los dem\u00e1s factores de riesgo identificados en las secciones \"Risk Factors\" (\"Factores de riesgo\") y \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" (\"An\u00e1lisis y discusi\u00f3n de la gerencia sobre la condici\u00f3n financiera y los resultados de las operaciones\") del informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2020 y en los informes trimestrales subsiguientes en el Formulario 10-Q presentados ante la Comisi\u00f3n de Bolsa y Valores (SEC). Advertimos a los inversionistas no depositar un nivel de confianza indebido en las declaraciones prospectivas contenidas en este comunicado de prensa. Le recomendamos leer nuestros archivos registrados ante la SEC, disponibles en\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2403161286&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1771995205%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3300061709&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3289188763%26u%3Dhttps%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com), para analizar estos y otros riesgos e incertidumbres. Las declaraciones prospectivas contenidas en este comunicado de prensa se refieren solamente a la fecha en que este documento fue emitido y no estamos obligados a actualizar ni revisar ninguna de dichas declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos aquellos mencionados anteriormente. Los inversionistas actuales y potenciales, y otros interesados deben evaluar detenidamente estos riesgos e incertidumbres.\nContactos:\nInversionistas\nAlex Delacroix | 240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#2a43586a44455c4b5c4b5204494547)\nMedios:\nAli Chartan | 240-720-7804\n[[email protected]](/cdn-cgi/l/email-protection#1b767e7f727a5b75746d7a6d7a6335787476)\nLogotipo:\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4098355291&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2132339007%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nFUENTE Novavax, Inc.\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/la-vacuna-de-novavax-nuvaxovid-tm-covid-19-autorizada-en-la-union-europea-para-adolescentes-de-12-a-17-anos-837575764.html", "/in/news-releases/novavax-nuvaxovid-tm-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17-810530420.html", "/news-releases/novavax-nuvaxovid-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17-301580570.html", "/news-releases/l-utilisation-du-vaccin-contre-la-covid-19-nuvaxovid-tm-de-novavax-est-autorisee-sous-condition-au-sein-de-l-union-europeenne-pour-les-adolescents-ages-de-12-a-17-ans-887218858.html", "/news-releases/novavax-nuvaxovid-tm-covid-19-impfstoff-in-der-europaischen-union-fur-jugendliche-im-alter-von-12-bis-17-jahren-unter-vorbehalt-zugelassen-825562694.html", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2861931460&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4051581382%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-23-Novavax-COVID-19-Vaccine-Nuvaxovid-TM-Recommended-for-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-by-CHMP-for-Adolescents-Aged-12-Through-17%26a%3DJune%2B23%252C%2B2022&a=23+de+junio+de+2022.", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=972467163&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3028641640%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3Dpediatric%2Bexpansion&a=expansi%C3%B3n+pedi%C3%A1trica", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2632041598&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D697197056%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D3782079808%2526u%253Dhttps%25253A%25252F%25252Fir.novavax.com%25252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%2526a%253DDecember%26a%3DDecember%2B2021&a=diciembre+de+2021", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=574237381&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3307428078%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-03-22-Novavax-and-Serum-Institute-of-India-Announce-First-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-Adolescents-12-to-18-in-India%26a%3DIndia&a=India", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=304390253&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1662690841%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D1545350530%2526u%253Dhttps%25253A%25252F%25252Fwww.ema.europa.eu%25252Fen%25252Fmedicines%25252Fhuman%25252FEPAR%25252Fnuvaxovid%2526a%253DEuropean%252BMedicines%252BAgency%26a%3DEuropean%2BMedicines%2BAgency&a=Agencia+Europea+de+Medicamentos", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=1578647828&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D4294773337%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3490095-1%2526h%253D2784477625%2526u%253Dhttps%25253A%25252F%25252Fec.europa.eu%25252Fcommission%25252Fpresscorner%25252Fdetail%25252Fen%25252Fip_21_6966%2526a%253DEuropean%252BCommission%26a%3DEuropean%2BCommission&a=Comisi%C3%B3n+Europea", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2184205737&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1723901377%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3432645-1%2526h%253D3408202368%2526u%253Dhttps%25253A%25252F%25252Fwww.novavaxcovidvaccine.com%25252F%2526a%253Dglobal%252Bauthorization%252Bwebsite%26a%3DNovavax%2Bglobal%2Bauthorization%2Bwebsite&a=Sitio+web+de+autorizaci%C3%B3n+global+de+Novavax", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=599448890&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1671020019%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4040707067&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2148733100%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=132730778&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1672205823%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=734026&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2136702606%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D91088807%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D1725473980%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D2733326919%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D853375093%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D1325598136%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D2935962557%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D1508558197%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3158017-1%252525252525252526h%25252525252525253D3702938248%252525252525252526u%25252525252525253Dhttps%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.linkedin.com%2525252525252525252Fcompany%2525252525252525252Fnovavax%2525252525252525252F%252525252525252526a%25252525252525253DLinkedIn%2525252525252526a%252525252525253DLinkedIn%25252525252526a%2525252525253DLinkedIn%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%2525&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=2403161286&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D1771995205%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=3300061709&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D3289188763%26u%3Dhttps%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com", "/cdn-cgi/l/email-protection#2a43586a44455c4b5c4b5204494547", "/cdn-cgi/l/email-protection#1b767e7f727a5b75746d7a6d7a6335787476", "https://c212.net/c/link/?t=0&l=es&o=3585705-1&h=4098355291&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3585705-1%26h%3D2132339007%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/energy-latest-news/mining-metals-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}